Figure 6.

Spontaneous synchronous ethosuximide-sensitive spike-wave seizures in α1G transgenic mice. Representative bilateral cortical EEG recordings (L, left; R, right) of freely moving WT, α1G-Tg1, and α1G-Tg2 mice demonstrating that both the α1G-Tg1 and α1G-Tg2 mice develop spike-wave seizures, while WT mice show normal EEG activity. Administration of the anti-epileptic drug ethosuximide (ETX) suppresses the spike-wave seizures produced in both the α1G-Tg1 and α1G-Tg2 mice. Comparison of the average number of observed spike-wave seizures per hour reveals an increased incidence in the α1G-Tg2 line (25.8 ± 4.9; ranging from 5 to 55 seizures/h; 12 h from 4 mice) over the α1G-Tg1 line (11.0 ± 2.4; ranging from 1 to 45 seizures/h; 23 h from 4 mice). Comparisons of individual SWD frequency and duration show no significant differences between the α1G-Tg1 (16 seizures from 6 mice) and α1G-Tg2 (16 seizures from 5 mice) lines.